Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by bit.bio
bit.bio Expands Executive Team with Appointment of Przemek Obloj as Chief Financial Officer
July 31, 2024
From
bit.bio
Via
Business Wire
bit.bio Launches ioAstrocytes, Advancing How Scientists Can Model the Human Brain
June 20, 2024
From
bit.bio
Via
Business Wire
Nobel Laureate Thomas Südhof and bit.bio CEO Mark Kotter to Lead Fireside Chat on Programming Human Cells at SynBioBeta
April 29, 2024
From
bit.bio
Via
Business Wire
bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease
March 05, 2024
From
bit.bio
Via
Business Wire
bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network
February 28, 2024
From
bit.bio
Via
Business Wire
Tickers
DNA
bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis (ALS)
December 06, 2023
From
bit.bio
Via
Business Wire
Scientists at King's College London and bit.bio Collaborate to Develop Multi-Cell Models of the Human Brain With Optimised Open-Source Protocols for Use by Any Researcher
November 24, 2023
From
bit.bio
Via
Business Wire
bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy
November 08, 2023
From
bit.bio
Via
Business Wire
bit.bio introduces first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease modelling and drug discovery
October 17, 2023
From
bit.bio
Via
Business Wire
bit.bio is Industrialising Human Cell Manufacturing, Unleashing the Potential of Synthetic Biology for Reproducible Research and Affordable Regenerative Medicines
June 15, 2023
From
bit.bio
Via
Business Wire
bit.bio Launches New Custom Disease Model Cells Offering, Advancing Disease Research and Drug Discovery
May 23, 2023
From
bit.bio
Via
Business Wire
bit.bio Expands Board of Directors With Appointment of Distinguished Investor, Philanthropist, and Scientist
May 11, 2023
From
bit.bio
Via
Business Wire
bit.bio Expands Its Portfolio With Three New Human Cell Products for Research and Drug Discovery in Neurodegenerative and Neurological Diseases
November 23, 2022
From
bit.bio
Via
Business Wire
bit.bio Expands Independent Ethics and Sustainability Board as Part of Commitment to Being a Purpose Driven Company
October 25, 2022
From
bit.bio
Via
Business Wire
bit.bio Adds Two New Human Cell Products to Address the Translation Gap and Accelerate Research and Drug Discovery for Neurodegenerative Disease
September 29, 2022
From
bit.bio
Via
Business Wire
bit.bio named Emerging Star at European Mediscience Awards 2022
June 17, 2022
From
bit.bio
Via
Business Wire
bit.bio Presents Data at ISSCR Demonstrating Their Platform’s Capability to Create Any Human Cell
June 16, 2022
From
bit.bio
Via
Business Wire
bit.bio Celebrates Double Award Win at Cambridge Science and Technology Awards 2022 Including Biotech of the Year for the Second Time in a Row
May 23, 2022
From
bit.bio
Via
Business Wire
bit.bio’s New Huntington’s Disease Human Cell Model Set to Accelerate Drug Discovery and Screening
May 09, 2022
From
bit.bio
Via
Business Wire
Bit.bio Appoints Accomplished Biotechnology Executive and Drug Developer Kathryn Corzo as Chief Operating Officer
November 17, 2021
From
Bit.bio
Via
Business Wire
bit.bio Raises in Excess of $100 Million in First Close of Series B Financing
November 05, 2021
From
bit.bio
Via
Business Wire
bit.bio expands Board of Directors with the Appointment of Entrepreneurs and a Nobel Laureate
October 28, 2021
From
bit.bio
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.